Astrocytoma other diagnostic studies
|
Astrocytoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Study |
|
Astrocytoma other diagnostic studies On the Web |
|
American Roentgen Ray Society Images of Astrocytoma other diagnostic studies |
|
Risk calculators and risk factors for Astrocytoma other diagnostic studies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D.
Overview
Other Diagnostic Studies
Biopsy is helpful in the diagnosis of astrocytomas:[1][2][3]
- Astrocytomas are histologically heterogenous
- Obtaining small specimen from astrocytomas might lead to false diagnosis.
- For lesions with areas of contrast enhancement the specimen should be obtained from those areas.
- For lesions with no intra-tumor enhancement the specimen should be obtained from the center of the tumor.
Pathological findings diagnostic of astrocytoma include:[4]
- Grade 1: Cells appearance is normal and growth rate is slow.
- Grade 2: There might be some atypical cells inside tumor. Mitosis rate is relatively slow.
- Grade 3 and 4: Tumor cells are anaplastic and malignant with high mitosis rate.
Molecular findings diagnostic of astrocytoma include:[5]
| • Stem cell • Precursor cell • Glial cell | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| IDH1 mutation | • 10q loss • PTEN mutation • EGFR overexpression • MDM2 overexpression | • KIAA1549-BRAF fusion • MAPK/ERK abnormalities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| • p53 mutation • PDGF/PDGFRA overexpression | Primary glioblastoma grade IV | Pilocytic astrocytoma grade I | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Diffuse astrocytoma grade II | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Chr 19q loss | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Anaplastic astocytoma grade III | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 10q loss | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Glioblastoma (secondary) grade IV | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
References
- ↑ Jackson RJ, Fuller GN, Abi-Said D, Lang FF, Gokaslan ZL, Shi WM, Wildrick DM, Sawaya R (July 2001). "Limitations of stereotactic biopsy in the initial management of gliomas". Neuro-oncology. 3 (3): 193–200. doi:10.1093/neuonc/3.3.193. PMC 1920616. PMID 11465400.
- ↑ McGirt MJ, Villavicencio AT, Bulsara KR, Friedman AH (April 2003). "MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen". Surg Neurol. 59 (4): 277–81, discussion 281–2. PMID 12748009.
- ↑ Son BC, Kim MC, Choi BG, Kim EN, Baik HM, Choe BY, Naruse S, Kang JK (2001). "Proton magnetic resonance chemical shift imaging (1H CSI)-directed stereotactic biopsy". Acta Neurochir (Wien). 143 (1): 45–9, discussion 49–50. PMID 11345717.
- ↑ Mattle, Heinrich (2017). Fundamentals of neurology : an illustrated guide. Stuttgart New York: Thieme. ISBN 9783131364524.
- ↑ Ellison, David (2013). Neuropathology : a reference text of CNS pathology. Edinburgh New York: Mosby. ISBN 0723435154.